Related Experiment Video
Updated: Jul 13, 2026

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Pharmacokinetic interaction between evodiamine and doxofylline in rats
Yuxian Lin1, Yongle Yang2, Wang Luo3
1The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, Zhejiang, China/ School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.
Evodiamine (EVO) significantly alters the pharmacokinetics of Doxofylline (DFL) and its metabolite, theophylline (TPL), in rats. EVO prolonged DFL retention while reducing TPL bioavailability, highlighting potential drug interactions.
Area of Science:
- Pharmacology
- Drug Metabolism
- Pharmacokinetics
Background:
- Doxofylline (DFL) is a key medication for asthma and COPD.
- Evodiamine (EVO), a traditional Chinese medicine alkaloid, treats various conditions.
- Drug interactions are common due to shared Cytochrome P450 metabolism.
Purpose of the Study:
- To investigate the pharmacokinetic interactions between Doxofylline (DFL) and Evodiamine (EVO).
- To assess the impact of EVO on DFL and its metabolite, theophylline (TPL), in rats.
Main Methods:
- Rats received daily oral Evodiamine (EVO) or placebo for one week.
- Doxofylline (DFL) was administered on day 7.
- Plasma concentrations of DFL and TPL were quantified using LC-MS/MS.
Main Results:
- Evodiamine (EVO) significantly increased Doxofylline (DFL) retention time and volume of distribution.
- EVO administration decreased theophylline (TPL) bioavailability (AUC) and MRT.
- EVO enhanced theophylline (TPL) clearance (CLz/F) and volume of distribution (Vz/F).
Conclusions:
- Co-administration of Evodiamine (EVO) and Doxofylline (DFL) substantially alters their pharmacokinetic profiles in rats.
- EVO prolongs DFL retention and reduces TPL bioavailability, indicating a significant drug interaction.
- Close monitoring and further research are essential to understand EVO's impact on DFL and TPL pharmacokinetics.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship
